Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Sagimet Biosciences Inc.
13G
SGMT · 786700104
|
7.6% |
10/7/2026
Event 9/30/2026
|
|||
| Commodore Capital LP | 7.6% | ||||
| Commodore Capital Master LP | 7.6% | ||||
| Robert Egen Atkinson | 7.6% | ||||
| Michael Kramarz | 7.6% | ||||
|
Surrozen, Inc./DE
13G
SRZN · 86889P208
|
7.5% |
10/1/2026
Event 9/24/2026
|
|||
| Commodore Capital LP | 7.5% | ||||
| Commodore Capital Master LP | 7.5% | ||||
| Robert Egen Atkinson | 7.5% | ||||
| Michael Kramarz | 7.5% | ||||
|
JATT III Acquisition Corp
13G
G5080G109
|
5.2% |
9/2/2026
Event 8/26/2026
|
|||
| Commodore Capital LP | 5.2% | ||||
| Commodore Capital Master LP | 5.2% | ||||
| Robert Egen Atkinson | 5.2% | ||||
| Michael Kramarz | 5.2% | ||||
|
InflaRx N.V.
13G
IFRX · N44821101
|
5.1% |
8/17/2026
Event 8/10/2026
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
| Robert Egen Atkinson | 5.1% | ||||
| Michael Kramarz | 5.1% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 2
PALI · 696389402
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
| Robert Egen Atkinson | 0% | ||||
| Michael Kramarz | 0% | ||||
|
JATT II Acquisition Corp.
13G/A
Amendment 1
JATT · G50765109
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
| Robert Egen Atkinson | 0% | ||||
| Michael Kramarz | 0% | ||||
|
Immunic, Inc.
13G/A
Amendment 1
IMUX · 4525EP200
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
Amendment 1
KPTI · 48576U205
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
| Robert Egen Atkinson | 0% | ||||
| Michael Kramarz | 0% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 3
RLAY · 75943R102
|
5.5% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
SAB Biotherapeutics, Inc.
13G/A
Amendment 1
SABS · 78397T202
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Definium Therapeutics, Inc.
13G/A
Amendment 3
DFTX · 24477V105
|
1.8% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 1.8% | ||||
| Commodore Capital Master LP | 1.8% | ||||
| Robert Egen Atkinson | 1.8% | ||||
| Michael Kramarz | 1.8% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 3
VTGN · 92840H400
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Research Alliance Corp IV
13G
RACD · G75228109
|
5.5% |
7/20/2026
Event 7/13/2026
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
Avalo Therapeutics, Inc.
13G
AVTX · 05338F306
|
9.9% |
6/18/2026
Event 6/11/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
EyePoint, Inc.
13G
EYPT · 30233G209
|
5.1% |
6/3/2026
Event 5/27/2026
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
| Robert Egen Atkinson | 5.1% | ||||
| Michael Kramarz | 5.1% | ||||
|
Editas Medicine, Inc.
13G
EDIT · 28106W103
|
9.9% |
6/2/2026
Event 5/26/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Research Alliance Corp III
13G
RACC · G75226103
|
5.5% |
5/28/2026
Event 5/20/2026
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 4
ELVN · 29337E102
|
7.7% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 7.7% | ||||
| Commodore Capital Master LP | 7.7% | ||||
| Robert Egen Atkinson | 7.7% | ||||
| Michael Kramarz | 7.7% | ||||
|
PepGen Inc.
13G/A
Amendment 1
PEPG · 713317105
|
6.5% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 6.5% | ||||
| Commodore Capital Master LP | 6.5% | ||||
| Robert Egen Atkinson | 6.5% | ||||
| Michael Kramarz | 6.5% | ||||
|
Tyra Biosciences, Inc.
13G/A
Amendment 2
TYRA · 90240B106
|
4.2% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 4.2% | ||||
| Commodore Capital Master LP | 4.2% | ||||
| Robert Egen Atkinson | 4.2% | ||||
| Michael Kramarz | 4.2% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 1
PALI · 696389402
|
7.2% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 7.2% | ||||
| Commodore Capital Master LP | 7.2% | ||||
| Robert Egen Atkinson | 7.2% | ||||
| Michael Kramarz | 7.2% | ||||
|
LB Pharmaceuticals Inc
13G/A
Amendment 2
LBRX · 50180M108
|
6.8% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 6.8% | ||||
| Commodore Capital Master LP | 6.8% | ||||
| Robert Egen Atkinson | 6.8% | ||||
| Michael Kramarz | 6.8% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 1
IKT · 45719W205
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 2
ANRO · 02157Q109
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Relmada Therapeutics, Inc.
13G
RLMD · 75955J402
|
5.1% |
5/4/2026
Event 4/27/2026
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
| Robert Egen Atkinson | 5.1% | ||||
| Michael Kramarz | 5.1% | ||||
|
JATT II Acquisition Corp.
13G
JATT · G50765109
|
6.4% |
4/24/2026
Event 4/17/2026
|
|||
| Commodore Capital LP | 6.4% | ||||
| Commodore Capital Master LP | 6.4% | ||||
| Robert Egen Atkinson | 6.4% | ||||
| Michael Kramarz | 6.4% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U205
|
9.9% |
4/2/2026
Event 3/26/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
AN2 Therapeutics, Inc.
13G
ANTX · 037326105
|
9.9% |
3/16/2026
Event 3/9/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
PepGen Inc.
13G
PEPG · 713317105
|
5.1% |
3/11/2026
Event 3/4/2026
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
| Robert Egen Atkinson | 5.1% | ||||
| Michael Kramarz | 5.1% | ||||
|
Immunic, Inc.
13G
IMUX · 4525EP101
|
9.9% |
2/24/2026
Event 2/17/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Cogent Biosciences, Inc.
13G/A
Amendment 2
COGT · 19240Q201
|
1.8% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 1.8% | ||||
| Commodore Capital Master LP | 1.8% | ||||
| Robert Egen Atkinson | 1.8% | ||||
| Michael Kramarz | 1.8% | ||||
|
Perceptive Capital Solutions Corp
13G/A
Amendment 1
PCSC · G70077105
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
|
Terns Pharmaceuticals, Inc.
13G/A
Amendment 2
TERN · 880881107
|
1.4% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 1.4% | ||||
| Commodore Capital Master LP | 1.4% | ||||
| Robert Egen Atkinson | 1.4% | ||||
| Michael Kramarz | 1.4% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 2
VTGN · 92840H400
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 2
DRUG · 10919W405
|
0.3% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 0.3% | ||||
| Commodore Capital Master LP | 0.3% | ||||
|
Definium Therapeutics, Inc.
13G/A
Amendment 2
DFTX · 24477V105
|
7.2% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 7.2% | ||||
| Commodore Capital Master LP | 7.2% | ||||
| Robert Egen Atkinson | 7.2% | ||||
| Michael Kramarz | 7.2% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 1
ANRO · 02157Q109
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Perspective Therapeutics, Inc.
13G
CATX · 46489V302
|
9.9% |
2/9/2026
Event 2/2/2026
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Century Therapeutics, Inc.
13G
IPSC · 15673T100
|
7.1% |
1/16/2026
Event 1/9/2026
|
|||
| Commodore Capital LP | 7.1% | ||||
| Commodore Capital Master LP | 7.1% | ||||
| Robert Egen Atkinson | 7.1% | ||||
| Michael Kramarz | 7.1% | ||||
|
Amylyx Pharmaceuticals, Inc.
13G
AMLX · 03237H101
|
5.1% |
11/17/2025
Event 11/10/2025
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
| Robert Egen Atkinson | 5.1% | ||||
| Michael Kramarz | 5.1% | ||||
|
Viridian Therapeutics, Inc.\DE
13G/A
Amendment 1
VRDN · 92790C104
|
3.9% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 3.9% | ||||
| Commodore Capital Master LP | 3.9% | ||||
|
Celldex Therapeutics, Inc.
13G/A
Amendment 1
CLDX · 15117B202
|
4.6% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 4.6% | ||||
| Commodore Capital Master LP | 4.6% | ||||
|
Nurix Therapeutics, Inc.
13G/A
Amendment 1
NRIX · 67080M103
|
4.9% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 4.9% | ||||
| Commodore Capital Master LP | 4.9% | ||||
|
Cogent Biosciences, Inc.
13G/A
Amendment 1
COGT · 19240Q201
|
7.2% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 7.2% | ||||
| Commodore Capital Master LP | 7.2% | ||||
| Robert Egen Atkinson | 7.2% | ||||
| Michael Kramarz | 7.2% | ||||
|
Terns Pharmaceuticals, Inc.
13G/A
Amendment 1
TERN · 880881107
|
6.5% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 6.5% | ||||
| Commodore Capital Master LP | 6.5% | ||||
| Robert Egen Atkinson | 6.5% | ||||
| Michael Kramarz | 6.5% | ||||
|
Cidara Therapeutics, Inc.
13G/A
Amendment 1
CDTX · 171757206
|
2.0% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 2.0% | ||||
| Commodore Capital Master LP | 2.0% | ||||
| Robert Egen Atkinson | 2.0% | ||||
| Michael Kramarz | 2.0% | ||||
|
Tyra Biosciences, Inc.
13G/A
Amendment 1
TYRA · 90240B106
|
6.3% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 6.3% | ||||
| Commodore Capital Master LP | 6.3% | ||||
| Robert Egen Atkinson | 6.3% | ||||
| Michael Kramarz | 6.3% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 2
RLAY · 75943R102
|
9.9% |
11/14/2025
Event 9/30/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Alto Neuroscience, Inc.
13G
ANRO · 02157Q109
|
9.8% |
10/27/2025
Event 10/20/2025
|
|||
| Commodore Capital LP | 9.8% | ||||
| Commodore Capital Master LP | 9.8% | ||||
| Robert Egen Atkinson | 9.8% | ||||
| Michael Kramarz | 9.8% | ||||
|
Palisade Bio, Inc.
13G
PALI · 696389402
|
9.9% |
10/8/2025
Event 10/1/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Sab Biotherapeutics, Inc.
13G
SABS · 78397T202
|
9.9% |
10/3/2025
Event 9/26/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
LB Pharmaceuticals Inc
13G
LBRX · 50180M108
|
5.5% |
9/18/2025
Event 9/11/2025
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
Terns Pharmaceuticals, Inc.
13G
TERN · 880881107
|
5.3% |
9/16/2025
Event 9/9/2025
|
|||
| Commodore Capital LP | 5.3% | ||||
| Commodore Capital Master LP | 5.3% | ||||
| Robert Egen Atkinson | 5.3% | ||||
| Michael Kramarz | 5.3% | ||||
|
Assembly Biosciences, Inc.
13G
ASMB · 045396207
|
9.9% |
8/15/2025
Event 8/8/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Cogent Biosciences, Inc.
13G
COGT · 19240Q201
|
5.5% |
8/14/2025
Event 7/7/2025
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
Solid Biosciences Inc.
13G/A
Amendment 1
SLDB · 83422E204
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 1
RLAY · 75943R102
|
7.8% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 7.8% | ||||
| Commodore Capital Master LP | 7.8% | ||||
| Robert Egen Atkinson | 7.8% | ||||
| Michael Kramarz | 7.8% | ||||
|
Neurogene Inc.
13G/A
Amendment 1
NGNE · 64135M105
|
3.0% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 3.0% | ||||
| Commodore Capital Master LP | 3.0% | ||||
|
Merus N.V.
13G/A
Amendment 1
MRUS · N5749R100
|
4.7% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 4.7% | ||||
| Commodore Capital Master LP | 4.7% | ||||
|
Enliven Therapeutics, Inc.
13G/A
Amendment 3
ELVN · 29337E102
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 9.9% | ||||
| Commodore Capital Master LP | 9.9% | ||||
| Robert Egen Atkinson | 9.9% | ||||
| Michael Kramarz | 9.9% | ||||
|
Cardiff Oncology, Inc.
13G/A
Amendment 1
CRDF · 14147L108
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 0% | ||||
| Commodore Capital Master LP | 0% | ||||
|
Cogent Biosciences, Inc.
13G/A
Amendment 5
COGT · 19240Q201
|
4.6% |
8/14/2025
Event 6/30/2025
|
|||
| Commodore Capital LP | 4.6% | ||||
| Commodore Capital Master LP | 4.6% | ||||
|
Cidara Therapeutics, Inc.
13G
CDTX · 171757206
|
5.5% |
7/2/2025
Event 6/25/2025
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||
| Robert Egen Atkinson | 5.5% | ||||
| Michael Kramarz | 5.5% | ||||
|
Relay Therapeutics, Inc.
13G
RLAY · 75943R102
|
5.8% |
5/15/2025
Event 5/8/2025
|
|||
| Commodore Capital LP | 5.8% | ||||
| Commodore Capital Master LP | 5.8% | ||||
|
Tyra Biosciences, Inc.
13G
TYRA · 90240B106
|
5.2% |
5/14/2025
Event 5/7/2025
|
|||
| Commodore Capital LP | 5.2% | ||||
| Commodore Capital Master LP | 5.2% | ||||
|
Viridian Therapeutics, Inc.
13G
VRDN · 92790C104
|
5.3% |
4/11/2025
Event 4/4/2025
|
|||
| Commodore Capital LP | 5.3% | ||||
| Commodore Capital Master LP | 5.3% | ||||
|
Celldex Therapeutics, Inc.
13G
CLDX · 15117B202
|
5.0% |
4/10/2025
Event 4/3/2025
|
|||
| Commodore Capital LP | 5.0% | ||||
| Commodore Capital Master LP | 5.0% | ||||
|
Solid Biosciences Inc.
13G
SLDB · 83422E204
|
7.6% |
2/25/2025
Event 2/18/2025
|
|||
| Commodore Capital LP | 7.6% | ||||
| Commodore Capital Master LP | 7.6% | ||||
|
Nkarta, Inc.
13G/A
Amendment 2
NKTX · 65487U108
|
0.5% |
2/14/2025
Event 12/31/2024
|
|||
| Commodore Capital LP | 0.5% | ||||
| Commodore Capital Master LP | 0.5% | ||||
|
Celcuity Inc.
13G/A
Amendment 5
CELC · 15102K100
|
2.9% |
2/14/2025
Event 12/31/2024
|
|||
| Commodore Capital LP | 2.9% | ||||
| Commodore Capital Master LP | 2.9% | ||||
|
Nurix Therapeutics, Inc.
13G
NRIX · 67080M103
|
5.1% |
2/14/2025
Event 2/7/2025
|
|||
| Commodore Capital LP | 5.1% | ||||
| Commodore Capital Master LP | 5.1% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 1
DRUG · 10919W405
|
7.2% |
2/14/2025
Event 12/31/2024
|
|||
| Commodore Capital LP | 7.2% | ||||
| Commodore Capital Master LP | 7.2% | ||||
|
Cardiff Oncology, Inc.
13G
CRDF · 14147L108
|
8.1% |
12/17/2024
Event 12/10/2024
|
|||
| Commodore Capital LP | 8.1% | ||||
| Commodore Capital Master LP | 8.1% | ||||
|
Merus N.V.
13G
MRUS · N5749R100
|
5.5% |
12/16/2024
Event 12/9/2024
|
|||
| Commodore Capital LP | 5.5% | ||||
| Commodore Capital Master LP | 5.5% | ||||